IP Intensive: AstraZeneca visits the Supreme Court of Canada

As part of Osgoode's Intellectual Property Law & Technology Intensive Program, I had the distinct pleasure of working with the Legal Affairs team at AstraZeneca Canada. With a technical background in the life sciences and a keen interest in pursuing a legal career engaged in this field, having the opportunity to gain first hand experience […]

Bringing Biologics in from the Cold: Does Canada’s IP Regime Need a Booster?

As ratification stutters for the Comprehensive Economic and Trade Agreement (CETA), the much-maligned free-trade deal between Canada and the European Union, debate continues as to whether the Canadian intellectual property (IP) regime will provide adequate protection for innovative biologic medicines in relation to subsequent-entry biologics (SEBs). Biologic medicines are complex molecules derived from living organisms […]